IMNM NASDAQ
Immunome, Inc.
1W: +4.7%
1M: -13.4%
3M: -18.8%
YTD: -9.8%
1Y: +19.6%
3Y: +115.0%
5Y: +3.0%
$18.77
+0.88 (+4.92%)
Weekly Expected Move ±8.0%
$15
$17
$18
$19
$21
Credit Risk of going bust: lower than 84% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Immunome, Inc. would be worth roughly what it owes.
Total debt $4.6M against a stock market value of $2.21B.
Distance to default 11.03 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.3M (short-term plus half of long-term), stock volatility 61.1%; Altman Z'' 11.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Immunome, Inc. would be worth roughly what it owes.
Total debt $4.6M against a stock market value of $2.21B.
Distance to default 11.03 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.3M (short-term plus half of long-term), stock volatility 61.1%; Altman Z'' 11.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-01-06
Earliest Filing
2024-10-29
Latest Filing
partner: 5
acquirer: 1
target: 1
Counterparties (Filed by IMNM)
7 relationshipsCompanies named in IMNM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. | ZNTL | acquirer | Zentalis acquired Immunome's licensed assets via an Asset Purchase Agreement and received common stock as consideration. | 2024-10-29 | View |
| Zeno Management, Inc. | — | partner | Zeno Management, a wholly owned subsidiary of Zentalis, is a party to the Asset Purchase Agreement. | 2024-10-29 | View |
| Ayala Pharmaceuticals, Inc. | — | target | Target of asset purchase agreement for AL101 and AL102 programs | 2024-02-06 | View |
| Zentalis Pharmaceuticals, Inc. | ZNTL | partner | Immunome, Inc. entered into a license agreement and stock issuance agreement with Zentalis Pharmaceuticals, Inc. for ROR | 2024-01-08 | View |
| AbbVie Global Enterprises Ltd. | ABBV | partner | Collaboration and option agreement for target discovery and commercialization | 2023-01-06 | View |
| AbbVie | ABBV | partner | Collaboration and option agreement for target discovery and commercialization | 2023-01-06 | View |
| Whitehead Institute for Biomedical Research | — | partner | Partner in Exclusive Patent License Agreement and Letter Agreement regarding patent payments and milestones. | 2023-01-06 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-05 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-17 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-15 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-11 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-30 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-29 | Results of Operations and Financial Condition; Other Events | View | |
| 2025-01-23 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-29 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Completion o | Agreement Acquisition | View |
| 2024-10-08 | Other Events; Financial Statements and Exhibits | View | |
| 2024-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-13 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR